



Contents

Contributors xi

Preface xv

Acknowledgments xix

1. Introduction to vaccine development	1
<i>Katherine E. Odneal</i>	
Vaccines: the greatest advancement of modern medicine	1
A brief historical review	2
The foundation of vaccine development	3
A summary of current strategies in vaccine development	4
Adjuvants	6
Summary	7
References	7
2. Overview of vaccine adjuvants	9
<i>Rushit N. Lodaya, Sonia Gregory, Mansoor M. Amiji and Derek T. O'Hagan</i>	
Introduction	9
General classification of vaccine adjuvants	11
Specific types of adjuvants	13
Future considerations in the development of adjuvants	18
Conclusions	19
Trademark statement	20
References	20

3. Formulation design considerations and good practice for live attenuated vaccine development	27
<i>Lee C. Smith and Paul Nelson</i>	
Introduction	27
Development of products with the end in mind	29
Development by design	34
Summary	76
References	76
4. Subunit-based vaccines: challenges in developing protein-based vaccines	79
<i>Salvador F. Ausar, Nicholas R. Larson, Yangjie Wei, Akshay Jain and C. Russell Middaugh</i>	
Introduction	79
Similarities of vaccine proteins to therapeutic proteins	80
Pneumococcal protein-based vaccine development	82
Pneumococcal virulence factors	83
Licensed pneumococcal vaccines	84
Recombinant pneumococcal proteins as vaccine candidates	85
Alternative approaches for pneumococcal vaccines	91
Protective immunity against <i>Chlamydia trachomatis</i>	92
<i>Chlamydia trachomatis</i> vaccine candidates	93
Ricin vaccine candidates	101
NoV vaccine candidates	108
<i>Clostridium difficile</i> vaccine candidates	116
Acknowledgments	124
References	124

5. QbD approach to formulation development for protein-based vaccines	137
<i>Malte Meppen and Daniela Stranges</i>	
Scope and challenges of protein bases formulation development	137
Quality by design as a guiding principle in vaccine formulation development	138
Preformulation studies	143
Formulation development and optimization studies	145
Conclusion	155
Acknowledgments	155
References	155
6. pDNA and mRNA vaccines	157
<i>Kanwal Gill, Leanne Minall and Aslin Rodriguez Nassif</i>	
Introduction	157
Basic biology of pDNA and mRNA vaccines	162
Nucleic acid vaccine development	168
Process development; scalability and manufacturability	177
The future of nucleic acid vaccines	182
References	187
7. Antigen—adjuvant formulations—key considerations	207
<i>Deep Bhattacharya, Chris Wiley, Aaron Latal and Vamsi Krishna</i>	
Introduction	207
Considerations for antigen—adjuvant compatibility	209
Drug product design and considerations for dose preparation and administration	215

Container closure	217
Lyophilization of antigen–adjuvant formulation considerations	219
Summary	222
References	223
8. Suspension properties and characterization of aluminum-adjuvanted vaccines	225
<i>Alex Langford, Michael Bruchsaler and Manish Gupta</i>	
Introduction	225
Aluminum-containing adjuvant structure	231
Principles of suspension behavior	232
Properties and characterization	237
Considerations in vaccine development	254
Conclusion	260
References	260
9. Effect of shipping stresses on suspension vaccines	267
<i>Jianxin Guo and Parag Kolhe</i>	
Introduction	267
Interplay between particle size, charge, and settling rate	268
Effect of shipping stress on thermodynamic suspension stability	271
Impact of individual shipping stresses on redispersion time	272
Mitigation strategy to reduce high redispersion time	276
Summary and recommendations	276
References	277

10. Control strategy development guide for vaccine drug product	279
<i>Deep Bhattacharya and Parag Kolhe</i>	
Introduction to control strategy approach	279
Control strategy considerations	280
Application of control strategy concept	285
Raw material control strategy	293
Summary and considerations for control strategy	295
References	295
11. Lyophilized vaccine development	297
<i>Nicole M. Payton, Rushit N. Lodaya and Adora M. Padilla</i>	
Introduction	297
Overview of lyophilization formulation and process	299
Vaccine-specific considerations	309
Considerations for lyophilization cycle scale-up	319
Summary	322
References	322
12. Conventional and nontraditional delivery methods and routes of vaccine administration	329
<i>Roberta Antonia Diotti, Valeria Caputo and Giuseppe Andrea Sautto</i>	
The choice: the importance of the correct delivery system for an effective vaccination	329
Conventional delivery methods: subcutaneous and intramuscular route	330

Epidermis and dermis as new sites of vaccine delivery	334
Other areas of the body as targets for vaccine delivery	341
Conclusion	347
References	348

Index	357
-------	-----